SCHEMBL2178574

SCHEMBL2178574

COCCCOc1cc(CCc2ccc(NC(=O)c3ccc(F)cc3)cc2)cc(C(=O)Nc2nccs2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
GCK P35557 2/20 0.49
POLB P06746 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
ADORA2A P29274 7/20 0.48
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
AGER Q15109 1/20 0.48
PTPN1 P18031 1/20 0.48
PTPN11 Q06124 1/20 0.48
PTPN22 Q9Y2R2 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CYP3A4 P08684 1/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2180846 0.91 MAPT (0.49) MAPTGCKPOLBTDP1MEN1
SCHEMBL2177412 0.91 KCNK3 (0.53) MAPTGCKPOLBTDP1MEN1
SCHEMBL2178466 0.91 KCNK3 (0.48) MAPTGCKPOLBTDP1MEN1
SCHEMBL2178536 0.90 RAB9A (0.51) MAPTGCKPOLBTDP1ADORA2A
SCHEMBL2176230 0.89 AGER (0.57) MAPTGCKPOLBTDP1ADORA2A
SCHEMBL2178578 0.88 GCK (0.65) MAPTGCKPOLBTDP1ADORA2A
SCHEMBL2179714 0.87 AURKA (0.50) MAPTGCKPOLBTDP1MEN1
SCHEMBL2176499 0.86 ADORA2A (0.62) GCKMEN1KMT2AADORA2ANPC1
SCHEMBL2179784 0.86 SMN1; SMN2 (0.54) MAPTGCKNPC1RAB9ASMN1; SMN2
SCHEMBL2177984 0.85 ADORA2A (0.62) MAPTGCKPOLBTDP1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178765-A1 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2012-07-12 US claimed
WO-2011081280-A2 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2011-07-07 WO claimed
US-20120178765-A1 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2012-07-12 US disclosed
WO-2011081280-A2 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178765-A1 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF GCK, GCKR, HK1 MAPT 3236/4885GCK 1/4885POLB 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.